QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
QQQ   380.00 (+0.23%)
AAPL   148.85 (-0.31%)
MSFT   323.17 (+4.21%)
FB   312.22 (-1.14%)
GOOGL   2,924.35 (+4.96%)
TSLA   1,037.86 (+1.91%)
AMZN   3,392.49 (+0.49%)
NVDA   244.51 (-1.08%)
BABA   169.23 (-0.45%)
NIO   39.31 (-2.87%)
CGC   12.78 (-2.96%)
GE   103.85 (-3.34%)
AMD   122.28 (-0.53%)
MU   68.24 (-1.02%)
T   25.06 (-1.22%)
F   15.51 (-2.70%)
ACB   6.84 (-2.70%)
DIS   169.55 (-1.45%)
PFE   42.97 (-1.35%)
BA   206.61 (-1.53%)
AMC   34.76 (-3.58%)
NASDAQ:KZIA

Kazia Therapeutics Stock Forecast, Price & News

$10.52
+0.02 (+0.19 %)
(As of 10/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$10.40
$10.81
50-Day Range
$8.76
$11.64
52-Week Range
$5.55
$15.85
Volume
16,574 shs
Average Volume
80,339 shs
Market Capitalization
$138.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
2.74
30 days | 90 days | 365 days | Advanced Chart
Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kazia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Kazia Therapeutics logo

About Kazia Therapeutics

Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KZIA
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$710,000.00
Book Value
$1.00 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$138.87 million
Next Earnings Date
1/6/2022 (Estimated)
Fiscal Year End
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

1006th out of 1,372 stocks

Pharmaceutical Preparations Industry

486th out of 669 stocks

Analyst Opinion: 3.5Community Rank: 3.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

Is Kazia Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kazia Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kazia Therapeutics stock.
View analyst ratings for Kazia Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Kazia Therapeutics?

Wall Street analysts have given Kazia Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kazia Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Kazia Therapeutics?

Kazia Therapeutics saw a decline in short interest in October. As of October 15th, there was short interest totaling 3,700 shares, a decline of 67.8% from the September 30th total of 11,500 shares. Based on an average daily volume of 24,900 shares, the short-interest ratio is currently 0.1 days.
View Kazia Therapeutics' Short Interest
.

When is Kazia Therapeutics' next earnings date?

Kazia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, January 6th 2022.
View our earnings forecast for Kazia Therapeutics
.

How has Kazia Therapeutics' stock been impacted by COVID-19?

Kazia Therapeutics' stock was trading at $3.98 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KZIA shares have increased by 164.3% and is now trading at $10.52.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KZIA?

2 equities research analysts have issued twelve-month price objectives for Kazia Therapeutics' shares. Their forecasts range from $17.00 to $18.00. On average, they expect Kazia Therapeutics' share price to reach $17.50 in the next twelve months. This suggests a possible upside of 66.3% from the stock's current price.
View analysts' price targets for Kazia Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • James Garner, Chief Executive Officer, MD & Executive Director
  • Gabrielle Heaton, Director-Finance & Administration
  • Catherine Hill, Secretary

What other stocks do shareholders of Kazia Therapeutics own?

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Who are Kazia Therapeutics' major shareholders?

Kazia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Total Clarity Wealth Management Inc. (0.04%).

Which institutional investors are buying Kazia Therapeutics stock?

KZIA stock was purchased by a variety of institutional investors in the last quarter, including Total Clarity Wealth Management Inc..

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $10.52.

How much money does Kazia Therapeutics make?

Kazia Therapeutics has a market capitalization of $138.87 million and generates $710,000.00 in revenue each year. The company earns $-8.37 million in net income (profit) each year or ($1.30) on an earnings per share basis.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

Where are Kazia Therapeutics' headquarters?

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at (129) 472-4101 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.